Drugs / Bafetinib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01234740 | Dec 2010 → Mar 2013 | adult anaplastic ependymoma, adult glioblastoma, anaplastic astrocytoma, anaplastic oligoastrocytoma +4 | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00352677 | Jul 2006 → May 2008 | acute lymphoblastic leukemia, chronic myeloid leukemia | CytRx | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01215799 | Aug 2010 → Sep 2011 | hormone-resistant prostate carcinoma | CytRx | Completed | No outcome recorded |
| Phase 2 | NCT01144260 | Jun 2010 → Dec 2011 | B-cell chronic lymphocytic leukemia | CytRx | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bafetinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01215799 ↗ |
| Known as | BAFETINIB (INNO-406) | ChEMBL registry synonym — accepted as the source's own label CHEMBL206834 ↗ |
| Known as | CNS-9 | ChEMBL registry synonym — accepted as the source's own label CHEMBL206834 ↗ |
| Known as | INNO-406 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00352677 ↗ |
| Known as | LYN-IN-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL206834 ↗ |
| Known as | NS-187 | ChEMBL registry synonym — accepted as the source's own label CHEMBL206834 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase ABL inhibitor” CHEMBL206834 ↗1“inhibiting Lyn kinase” NCT01144260 ↗ |
| Modality | Small molecule | — CHEMBL206834 ↗ |
| Route | Oral | “when administered as a daily oral agent” NCT00352677 ↗ |
| Target | ABL1 | “Tyrosine-protein kinase ABL inhibitor” CHEMBL206834 ↗ |
| Target | LYN | “targeting both bcr/abl and Lyn kinases” NCT01144260 ↗ |